The cornerstone of the initiative is the MMRF CoMMpass study, which is designed to follow 1,000 newly diagnosed multiple myeloma patients over five years to understand the molecular changes underpinning the progress of the disease...Vanda said it intends to appeal the opinion and request a re-examination of the CHMP decision

The company expects to receive about $725,200 after sales commission and other expenses...Under the 2010 collaboration, Genmab is tasked with creating human antibodies to three central nervous system targets identified by Lundbeck

The alliance will involve researchers from both organizations working together to investigate new ways of treating neurological diseases such as Alzheimer's, Parkinson's and other related disorders...The goal will be to identify and validate drug targets, develop new therapeutics and evaluate them in proof-of-concept trials

The transaction is expected to close in early 2013...The single-tablet, combination regimen is designed to provide convenience for diabetes patients...marketing rights to canagliflozin except for parts of Asia

According to the approved product labeling, the treatment may now be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower IOP

Shares of Somaxon (NASDAQ:SOMX) soared on the buyout news, gaining 80.3 percent, or $1.18, to close Tuesday at $2.65. (See BioWorld Today, March 19, 2010, July 16, 2010, Aug. 26, 2010, and June 9, 2011...to identify and nominate highly differentiated backup and follow-on IAP inhibitors...Ltd., pursuant to the existing license, commercialization and supply agreement between Sucampo Pharma Ltd., SPI's subsidiary, and Abbott

Eisai has a pending new drug application for Aciphex delayed-release sprinkle capsules 5 mg and 10 mg for the proposed indication of gastroesophageal reflux disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children, ages 1 to 11

Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the Elan shareholders...Galderma will continue to supply Restylane and Perlane to Valeant under the same terms and conditions that the products are supplied to Medicis, while Valeant will make undisclosed up-front and royalty payments to Galderma on sales of Sculptra...To

The decision to delist stemmed from the firm's inability to maintain the continuous listing requirements...Payments to Isis could total $200 million, including license fees and regulatory milestones per program, plus additional double-digit royalties...Geron agreed to assign to TA Sciences Inc., of New York, those patents previously licensed to Asia Biotech, including intellectual property relating to telomerase activation technology

GlaxoSmithKline plc, of London, and the Fred Hutchinson Cancer Research Center entered a partnership to develop therapeutics to treat an inherited form of muscular dystrophy...The goal of the agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease

The company plans to direct its cash and other resources primarily to enable the achievement of important near-term milestones for its BCX4161 HAE, BCX4430 broad-spectrum antiviral and BCX5191 hepatitis C programs

Reddy's Laboratories Ltd., of Hyderabad, India, acquired exclusive marketing and sales rights to Pamorelin LA (triptorelin) Depot, by Debiopharm Group, of Lausanne, Switzerland, in India for locally advanced or metastatic, hormone-dependent prostate cancer

Janssen Biotech Inc., of Horsham, Pa., and Janssen Biologics B.V., of Leiden, Netherlands, both part of Johnson & Johnson, submitted a supplemental biologics license application (sBLA) to the FDA and a Type II Variation to the European Medicines Agency (EMA) requesting approval of Stelara (ustekinumab) to treat adult patients with active psoriatic arthritis...The FDA gave guidance and permission to Lipocine Inc., of Salt Lake City, for its Phase III study of oral testosterone replacement therapy

Preclinical treatment goals for the TNBC and IBC indications are two-pronged: as a tumor reduction agent in combination with other approved drugs in preoperative settings and as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients...Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the

The product is designed to treat chronic diabetic macular edema considered insufficiently responsive to available therapies...Ltd., of Tokyo, to develop bispecific antibodies based on Genmab's DuoBody platform

Astellas Pharma Inc., of Tokyo, said the FDA accepted for review its new drug application for tacrolimus extended-release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients. The PDUFA data will be July 21, 2013. AstraZeneca plc, of London, said it agreed with the FDA on label changes for Faslodex (fulvestrant) injection, updating the label with results and a Kaplan-Meier plot of the final overall survival (OS

In other news, Bayer said its BAY 86-6150 is being investigated in a Phase II/III study, dubbed TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete...In other news, Viralytics is offering shareholders up to $15,000 worth of shares at 30 cents each in a new underwritten share purchase plan to fund the company's intravenous cancer trial and the continued clinical research and development of Cavatak, its lead oncolytic virus candidate

To date, none of the gene targets associated with the obese phenotype has provided a viable drug therapy...The technology is designed to identify all antibodies of a specific target across large populations of lymphocytes...Sernova Corp., of London, Ontario, published a method to evaluate insulin-producing donor islets prior to transplant as a predictor of which transplants are most likely to reverse diabetes in Cell Transplantation

Its expenses related to the terminations will be $280,000 in the fourth quarter...Spherix Consulting will continue to be headed by Claire Kruger, who resigned as CEO and director, as a division of ChromaDex, and Robert A. Lodder has taken over as principal executive officer of Spherix Inc., and a number of board members have resigned...Synthetic Biologics said it intends to develop an oral beta-lactamase enzyme product candidate, SYN-004, which is designed to be co-administered with certain beta